For years, the CRISPR-Cas9 genome technology has been reshaping genetic engineering, a precision tool to transform everything from agriculture to medicine. With its incredible efficiency ...

The CRISPR-Cas9 patent landscape remains complex and unsettled. The Federal Circuit’s latest decision in University of California v.

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

Researchers at UC Berkeley’s Innovative Genomics Institute, or IGI, developed a revolutionary treatment using CRISPR gene ...

Every living creature on Earth needs to protect itself from things that would do it harm. Bacteria are no different. And ...

Newly discovered weapons of bacterial self-defense take different approaches to achieving the same goal: preventing a virus from spreading through the bacterial population.

Casgevy (exagamglogene autotemcel or exa-cel) became the first drug based on the CRISPR/Cas9 gene-editing technology to be approved towards the end of last year, when it was cleared by the FDA for ...

When CRISPR was first introduced as a gene-editing tool in 2012, the world was in awe of all the possibilities it held — eventually earning its discoverers the Nobel Prize in Chemistry in 2020. Now, ...

The CRISPR-Cas9 platform will be used to delete the PD-1 gene in T cells extracted from trial participant’s blood. In healthy cells, an activated PD-1 gene results in the production of the PD-1 ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 2,899 calls trading, 1.4x expected, and implied vol increasing almost 2 points to 61.27%. Jun-25 30 calls and Oct-25 40 calls are ...